MabVax Therapeutics Holdings Inc

MabVax Therapeutics — Technical Presentation (April 2017)

57 slides from MabVax Therapeutics's technical presentation, Apr 7, 2017

  1. Slide 1: MabVax Therapeutics April 2017 Scientific Presentation

    L NASDAQ: MBVX NY, | MabVax therapeutics Clinical Stage Immuno-Oncology Company Developing Unique Human Monoclonal Antibody- Based Products for Difficult to Treat Cancers April 2017 Scientific Presentation David Hansen, President and CEO

  2. Slide 2: Disclaimer

    DISCLAIMER Forward Looking Statements This presentation contains forward-looking statements and projections. The company makes no express or implied representation or warranty as to the completeness of this information or, in the case of the projections, as to their attainability or the accuracy and

  3. Slide 3: MabVax Therapeutics Overview

    MABVAX THERAPEUTICS OVERVIEW Fully-human antibody discovery platform . € against multiple targets Products discovered from immune responses of cancer patients vaccinated against their solid tumors. Portfolio of antibodies Focused on translation of discoveries into clinical development Introduced thr

  4. Slide 4: Remarkable Clinical and Scientific Progress on Unique Therapeutic and Diagnostic Products

    REMARKABLE CLINICAL AND SCIENTIFIC PROGRESS ON UNIQUE THERAPEUTIC AND DIAGNOSTIC PRODUCTS MVT-5873 clinical trial demonstrates ear safety and efficacy MVT-2163 clinical trial demonstrates early safety and specificity MVT-1075 clinical trial authorized by FDA Expansion to other cancers expressing sam

  5. Slide 5: MabVax Has Rich Pipeline of Product Candidates

    MABVAX HAS RICH PIPELINE OF PRODUCT CANDIDATES Program MVT-5873 Therapeutic Monotherapy MVT-5873 Therapeutic Combination with soc MVT-2163 PET-Imaging MVT-1075 Radio- immunotherapy HuMab 5B1-ADC. HuMab 5B1- Fe Optimization Additional HuMab Antibodies in Early Development Mi MabVax therepeutice Indic

  6. Slide 6: Summary of Preclinical Data

    SUMMARY OF PRECLINICAL DATA Mi MabVax NASDAQ: MBVX therapeutics 6

  7. Slide 7: Sialyl Lewis A as a Viable Target for Cancer Therapeutics

    SIALYL LEWIs4 — AS A VIABLE TARGET FOR CANCER THERAPEUTICS ¢# HuMab-5B1 derived from a patient vaccinated with MabVax vaccine licensed from MSKCC CA19-9 detection in patients 4 @ Sialyl Lewis A antigen (SLEA or CA19-9) is the most frequently utilized and only Pancreas 92 validated serum marker for a

  8. Slide 8: Binding of Anti-SLEa mAbs to Multiple Tumor Cells

    BINDING OF ANTI-SLE“ MABS TO MULTIPLE TUMOR CELLS A DMS79 2. SSS= Poth Cobety:0en 9 2 00: Gamaty Oat 2 PO Gandy Gam A SCLC ‘ 15B1 r5HI1 |. eS Gee c. Pancreas F \ y & D. Ovary | aif) wt {\ | = wt E Melanoma oF alli, | ¥ Jlilias..___| = iB on B. HT29 Cc. BxPC3 —_ wesiee a —_ 3. 3. % r5B1 os 17E3 | 2 r

  9. Slide 9: HuMab-5B1 Is Highly Specific to SLEa Antigen by Glycan Array Analysis

    HuUMaAB-5B1 Is HIGHLY SPECIFIC TO SLE* ANTIGEN BY GLYCAN ARRAY ANALYSIS ‘Consortium for Functional Glycomics i “ * Novel fully-human IgG1 antibody | = ° Exceptional specificity i ce * Very good affinity (0.14nM) , ed * No cross-reactivity with related © ee accents: carbohydrate structures ° CDC and

  10. Slide 10: HuMab-5B1 Antibody Target Significantly Overexpressed on Multiple Cancers

    HUMAB-5B1 ANTIBODY TARGET SIGNIFICANTLY OVEREXPRESSED ON MULTIPLE CANCERS Potential therapeutic utility extends beyond pancreatic cancer A. Pancreatic ductal adenocarcinoma & B. Colon carcinoma C. Lung adenocarcinoma D. Urinary bladder, mucinous adenocarcinoma E. Colon metastatic to ovary FP. Breast

  11. Slide 11: HuMab-5B1 Is Internalized into Target Cells

    HUMAB-5B1 Is INTERNALIZED INTO TARGET CELLS Internalization Occurs Rapidly and Varies Between Cell Lines BxPC3 Capan-2 Mi MabVax therepeutice % Poritve seer eee eee ee ae) Houghton et al., J.Nuc.Med. 2016 Assay Principle The pH sensitive dye pHAb that becomes fluorescent at low pH encountered in end

  12. Slide 12: Non-Clinical Safety Studies Supporting MVT-5873

    NON-CLINICAL SAFETY STUDIES SUPPORTING MVT-5873 GLP in vitro tissue cross-reactivity studies with human and cynomolgus tissues ¢ Staining similar in human and cynomolgus providing toxicology species justification @ Staining observed in epithelial cell types and related extracellular mucus-like mater

  13. Slide 13: MVT-5873 Demonstrates Synergistic Anti-Tumor Effect with Chemotherapy

    MVT-5873 DEMONSTRATES SYNERGISTIC ANTI- TUMOR EFFECT WITH CHEMOTHERAPY IN MULTIPLE CANCER MODELS Relative Tumor Growth at Day 42 Relative Tumor Volume at Day 52 Gemcitabine/nab-Paclitaxel as Baseline Paclitaxel as Baseline BxPC3 Pancreatic Xenograft Model DMS 79 SCLC Xenograft Model = 2300 ) 3 nutes

  14. Slide 14: MVT-5873 Clinical Program Summary and Interim Data

    MVT-5873 CLINICAL PROGRAM SUMMARY AND INTERIM DATA Mi MabVax NASDAQ: MBVX therapeutics 14

  15. Slide 15: MVT-5873 Phase I Trial for PDAC & CA19-9 Positive Cancer

    MVT-5873 PHASE I TRIAL FOR PDAC & CA19-9 POSITIVE CANCER Open label, non-Randomized, Dose Escalation/Expansion Study Part 2: Combination with Chemotherapy Part 1: Single Agent Dose Escalation (gemcitabine/nab-paclitaxel) Stage 3 and 4 Patients With Progressive Disease Who Have Failed Other Treatment

  16. Slide 16: Interim MVT-5873 Pharmacokinetics Analysis

    INTERIM MVT-5873 PHARMACOKINETICS ANALYSIS PARAMETERS SIMILAR TO OTHER THERAPEUTIC ANTIBODIES ¢# MVT-5873 pharmacokinetics is evaluated in all cohorts ¢ Initial pharmacokinetic analysis includes different schedules of administration were analyzed using a compartment model ¢# Compartmental analysis h

  17. Slide 17: Interim Analysis Shows MVT-5873 Normalizes CA19-9 Levels

    INTERIM ANALYSIS SHOWS MVT-5873 NORMALIZES CA19-9 LEVELS IN PANCREATIC CANCER PATIENTS Circulating Levels of Antigen Normalized at Modest Doses of Antibody MVT-5873 Dose and Administration ¢ CA19-9 normalization post MVT-5873 administration appears to be dose dependent % CA19-9 Reduction (>95%, Norm

  18. Slide 18: Clinical Results to Date by Patient

    CLINICAL RESULTS TO DATE (03/07/17) BY PATIENT RECIST 1.1 RECIST 1.1 RECIST Lt —_ 9 of 25 Stable at cycles/1 RECIST Assessment Pe Patients 5 of 25 Stable at 4 cycles/2 RECIST Assessments 3 of 25 Stable at 3 cycles/3 RECIST Assessments I oo. 4 5 6 7 8 Time since start of treatment (months) Zmg/kg/eyc

  19. Slide 19: MVT-5873 Adverse Events Observed as a Monotherapy

    MVT-5873 ADVERSE EVENTS OBSERVED AS A MONOTHERAPY Number and grade of AEs 40 e S Number . S 40 Miviesvex therapeutics HM Definitely related HM Possibly related MVT-5873 adverse events include early onset infusion reactions and transient increases in liver function tests Infusion reactions are less l

  20. Slide 20: Unmet Clinical Need for Maintenance Therapy

    UNMET CLINICAL NEED FOR MAINTENANCE THERAPY ¢ Unmet need to extend and reinforce favorable results with induction therapies — Emerging strategies for long term control include pauses in therapy, re-challenges, and maintenance therapy — Commonly employed strategies are: * Switch to non-cross-resistan

  21. Slide 21: Value of New Maintenance Therapy for Pancreatic Cancer

    VALUE OF NEW MAINTENANCE THERAPY FOR PANCREATIC CANCER ¢ Only one comparison product approved for second line therapy: Merrimack’s ONIVYDE — Liposomal irinotecan and used only in combination with fluorouracil and leucovorin — OS improvement to 6.1 mos vs 4.2 mos and PFS improvement to 3.1 mos vs. 1.

  22. Slide 22: MVT-2163 Clinical Program Summary and Interim Data

    MVT-2163 CLINICAL PROGRAM SUMMARY AND INTERIM DATA Mi MabVax NASDAQ: MBVX therapeutics 22

  23. Slide 23: MVT-2163 Preclinical Development Efforts Translated into Positive Clinical Results

    MVT-2163 PRECLINICAL DEVELOPMENT EFFORTS HAVE TRANSLATED INTO POSITIVE CLINICAL RESULTS ¢ Based on in-depth review of clinical literature and input from thought leaders MabVax developed a rationale for a translational preclinical development plan to define: — Time required to obtain optimal scan ima

  24. Slide 24: MVT-2163 Imaging Compared to Standard PET Agent

    MVT-2163 IMAGING COMPARED TO STANDARD PET AGENT Mice orthotopically transplanted with BxPC3-luc pancreatic tumor xenografts JNM Rivers ‘The co-tegistration of FDG-PET and computed Acquired "Zr radiolabed-5B1 antibody (*°Z-5B1) tomography (CT) (left) and planar sections of PET image of the same mouse

  25. Slide 25: 89Zr-HuMab-5B1 Tumor Targeting in Shedding and Non-Shedding Models

    89ZR-HUMAB-5B1 TUMOR TARGETING OCCURS IN BOTH SHEDDING AND NON-SHEDDING CA19-9 MODELS DMS79 (SCLC) Does not shed detectable CA 19-9 2h 24h 48h 96h 120h Colo205 (Colon Cancer) High levels of shed antigen ~2300 U/ml for a 250mm? tumor Viola-Villegas, JNucMed 2013 \/ ee NASDAQ: MBVX | 25 W therapeutics

  26. Slide 26: MVT-5873 Pre-Administration Improves MVT-2163 PET Image Quality

    MVT-5873 PRE-ADMINISTRATION IMPROVES MVT-2163 PET IMAGE QUALITY Ne ete? }- . Inject radiolabeled ee . ™ . v ee ec: : Tumor Cells. Zr-SB1 Basia ae uptake and Tumor irr Capan-2 Xenografted Mice Interval between injections B5m Binh G4nr 24h No “cold” > a poor contrast ] 2 Inje gs inject unlabeled * ant

  27. Slide 27: Phase I Trial Design of MVT-2163 ImmunoPET Imaging Agent

    PHASE I TRIAL DESIGN OF MVT-2163 IMMUNOPET IMAGING AGENT PANCREATIC CANCER AND OTHER CA19-9 MALIGNANCIES Open label, non-randomized, dose escalation/expansion study Patients can roll to MVT-5873 Monotherapy Trial lation and Image Optimization : MVT-216 aero eeiceny Then combin: Additional Safety, PK

  28. Slide 28: Background: Comparable Antibody Therapies for Cancer Diagnosis and Treatment

    BACKGROUND: COMPARABLE ANTIBODY THERAPIES FOR CANCER DIAGNOSIS AND TREATMENT 8°Z1-Trastuzumab for metastatic M1J-J591 for hormone Minibody *-Zr-DF IAB2M, breast cancer refractory prostate cancer 50mg pre-administration ‘ / 4 W 4 & 4 < é ¢ 1 day ‘2 days 5 days ie — ba] ena Accumulation occurs over Pr

  29. Slide 29: 89Zr-DFO-HuMab5B1 (MVT-2163) Liver PET Images

    89ZR-DFO-HUMAB5B1 (MVT-2163) LIVER PET IMAGES Dose Level: 50mg/4.43 mCi +Patient: Female 158cm/64.2kg Pre-Dose CA19-9 = 2119 IU/mL, Post Dose CA19-9 = 51 IU/mL 1h 20h 44h 141h Mi MabVax NASDAQ: MBVX | 29 therepeutice

  30. Slide 30: Patient Example: MVT-2163 PET Images

    PATIENT EXAMPLE: MVT-2163 PET IMAGES LIVER METASTASIS AT HIGH SUV AS EARLY AS Day 1 POST DOSE MVT-2163 PET & Diagnostic CT Image Correlation Demonstrating Target Specificity Liver metastases SUVmax 75.2, Multiple nodes SUVmax 10.2 MVT-5873 47mg then 2h delay time MVT-2163 PET PET / Cr | 20h 141h Dia

  31. Slide 31: MVT-2163 Biodistribution

    MVT-2163 BIODISTRIBUTION COMPARABLE WITH j591 AND JAB2M MINIBODY TRACERS 3.0 = OIAb2M. ao @J591 250 =5B1 (0) S o o ° fa] Sag 3° ao 2 ¢ 00 alitit alidal Ss & & eS ss ss YE SEPE Ly my rs ~ S M MabVax Patient #9 NASDAQ: MBVX | 31 therapeutics

  32. Slide 32: Significant Accumulation of Antibody on Targeted Cancer

    SIGNIFICANT ACCUMULATION OF ANTIBODY ON TARGETED CANCER MVT-2163 Accumulates on Target without interference by CA19-9 Levels Patient administered 3 mg MVT-2163 Patient administered 3 mg MVT- (no MVT-5873 loading dose) 2163 (47 mg MVT-5873 loading dose) 3 ry % 30 as Eos ? 820 % 3% bn =. $10 SOmPA Nod

  33. Slide 33: MVT-2163 Product Opportunity

    MVT-2163 PRODUCT OPPORTUNITY MVT-2163 images tumor lesions not identified by diagnostic CT Staging newly diagnosed PDAC patients for surgery is limited by CT resolution — Only 20% deemed eligible for surgery and majority found inoperable during surgery — Problem: Incomplete disease dissemination ide

  34. Slide 34: MVT-1075 Program Summary and Product Opportunity

    MVT-1075 PROGRAM SUMMARY AND PRODUCT OPPORTUNITY Mi MabVax NASDAQ: MBVX therapeutics 34

  35. Slide 35: MVT-1075 Is Designed to Attack Primary Tumor and Metastatic Sites

    MVT-1075 Is DESIGNED TO ATTACK PRIMARY TUMOR AND METASTATIC SITES Attribute HuMab-5B1 Antibody CA19-9 is validated target for PDAC Effective Payload Lutetium radionuclide (7Lu) Multi-cell effective range for tumor cell killing Loading dose pharmacokinetics well established by MVT-2163 MabVax therape

  36. Slide 36: MVT-1075 Designed to Attack Primary Tumor and Metastatic Sites and Enhance Cell Death

    MVT-1075 Is DESIGNED TO ATTACK PRIMARY TUMOR AND METASTATIC SITES AND ENHANCE CELL DEATH Highly specific HuMab- 5B1 antibody conjugated to radionuclide (177Lu) MVT-2163 Phase I results demonstrate significant accumulation on tumor Rapid and significant internalization of antibody-radionuclide oN Eff

  37. Slide 37: MVT-1075 Radioimmunotherapy Preclinical Studies Demonstrate Tumor Growth Suppression

    MVT-1075 RADIOIMMUNOTHERAPY — PRECLINICAL STUDIES DEMONSTRATE SUBSTANTIAL TUMOR GROWTH SUPPRESSION AND TUMOR REGRESSION Biodistribution of 7 Lu-CHX-A”-DTPA-5B1 fs 277LU-CHX-A”-DTPA-5B1 © Control (PBS) = 5B1 0 > 130 2 = 300uGi 120 5 0) & 450uci 110: < wth 3 40 3 N=8 for all groups FI 80 i > 3 3 2 60.

  38. Slide 38: MVT-1075 HuMab-5B1 Radioimmunotherapy Orthotopic PDAC Model

    MVT-1075 HUMAB-5B1 RADIOIMMUNOTHERAPY ORTHOTOPIC PDAC MODEL DEMONSTRATES TUMOR REGRESSION BO Pre-treatment Post-treatment Collaboration with Jason S. Lewis, Ph.D. Member, Memorial Sloan-Kettering Cancer Center, Mi Vice Chairman & Chief Attending, Department of Radiology MabVax NASDAQ: MBVX 38

  39. Slide 39: Manufacturing, Quality, Distribution Established for Clinical Program

    MANUFACTURING, QUALITY, DISTRIBUTION ESTABLISHED FOR CLINICAL PROGRAM AND PATHWAY FOR COMMERCIALIZATION ¢@ MVT-1075 manufactured on a per patient basis ¢ Manufacturing established at experienced cGMP third party site @ Produced from a bulk conjugate intermediate as unit-of-use vials @ Process simila

  40. Slide 40: Phase I Trial of MVT-1075 Radioimmunotherapy

    PHASE I TRIAL OF MVT-1075 RADIOIMMUNOTHERAPY FOR PANCREATIC AND OTHER CA19-9 MALIGNANCIES Open label, Non-randomized, Dose Escalation Safety Study Establish Safety, Tolerability, Dosimetry & RP2D ration Phase I Dose E ion and Expansion onal dose udy design to determine MTD Histologically confirmed,

  41. Slide 41: MVT-1075 Unique Product with Significant Value Proposition

    MVT-1075 UNIQUE PRODUCT WITH SIGNIFICANT VALUE PROPOSITION Single doses of MVT-1075 demonstrate tumor regression in Compelling preclinical animal models of PDAC MVT-2163 clinical data have establish dosimetry, target specificity and high SUV values Prognosis for PDAC still poor. Must target primary

  42. Slide 42: MVT-1075 Product Opportunity

    MVT-1075 PRODUCT OPPORTUNITY ¢ Reduce disease burden by making more patients eligible for surgery — Given to newly diagnosed patients either before or after chemotherapy to reduce primary tumor size/spread and eliminate metastatic sites ¢ Applicable for multiple cancer types that are positive for CA

  43. Slide 43: Value Proposition for a New Radioimmunotherapy for Pancreatic Cancer

    VALUE PROPOSITION FOR A NEW RADIOIMMUNOTHERAPY FOR PANCREATIC CANCER ¢ Algeta’s Xofigo for castration-resistant prostate cancer — Xofigo (radium Ra 223) is radiotherapeutic alpha particle emitting product — Approved in US in May 2013 and EU in November 2013 — Development and commercialization deal w

  44. Slide 44: HuMab 5B-1 ADC Program Summary and Product Opportunity

    HUMAB 5B-1 ADC PROGRAM SUMMARY AND PRODUCT OPPORTUNITY Mi MabVax NASDAQ: MBVX therapeutics 44

  45. Slide 45: HuMab-5B1-Based Antibody Drug Conjugate (ADC)

    HUMAB-5B1-BASED ANTIBODY DRUG CONJUGATE (ADC) HuMab-5B1 has ideal characteristics for ADC ¢ Antibody is readily internalized ¢ Large number of targets on each cell ¢ Established targeting specificity and affinity ¢ Clinical validation ¢ Acceptable toxicology profile ¢ Multiple linker/toxin combinati

  46. Slide 46: Extensive ADC Evaluation

    EXTENSIVE ADC EVALUATION ¢ Multiple toxins evaluated — Saporin conjugated secondary antibody (Sawada et al. 2011) — Amanitin — MMAE, MMAF ¢ Developed internalization assay — Indirect or direct conjugated pH sensitive fluorophore (pHAb; Promega) ¢ Multiple linker technologies evaluated including — Ma

  47. Slide 47: HuMab-5B1 Is Internalized into Target Cells

    HUMAB-5B1 Is INTERNALIZED INTO TARGET CELLS Internalization Occurs Rapidly and Varies Between Cell Lines Assay Principle ¢ The pH sensitive dye pHAb that becomes fluorescent at low pH % Posttve BxPC3 : ! encountered in endosomes is conjugated to MVT-5873 or anti- human F(ab),. ¢ The percentage of fl

  48. Slide 48: Activity of Site-Specific MMAE-ADCs

    ACTIVITY OF SITE-SPECIFIC MMAE-ADCs In vitro cytotoxicity of chemoenzymatic site specific labeled MMAE-ADCs (Houghton et al., PNAS 2016) B-1,4-Galactosidase GalT(¥289L) DIBO-Toxin % Ns Ny Ny Unconjugated Ab Azide-Activated Ab Conjugated ADC (stable for long-term storage) DOL =3.4 IC50 (nM) SCLC Tcel

  49. Slide 49: Cytotoxicity of 5B1 ADCs on Tumor Cell Lines

    CYTOTOXICITY OF 5B1 ADCs ON TUMOR CELL LINES In vitro cytotoxicity of amanitin-ADCs on various cell lines Prat: BxPcs Plate 2: Capan2 Gu ‘ {cells ste’ |581-ADc| ADC : ; | { |colo20s | ++ | 0.159 | 1746 z ’ perme gs h, na [execs + | 2514 | 186.7 i vefmaite : fetes \capan-2 ++ | 0.043 | 45.2 5 3 jurka

  50. Slide 50: Efficacy in a Human Pancreatic Xenograft Model

    EFFICACY IN A HUMAN PANCREATIC XENOGRAFT MODEL HuMab-5B1 Antibody Drug Conjugate In Vivo Data (BxPC3 xenografts) Lysine Conjugated Amanitin Linker Optimization Study Demonstrates Demonstrates Efficacy Spectrum of Efficacy Mean Tumor Volume [600.00 _>—________-_ -»- PBS. iad “®ADCI 400.00 “eape2 300.

  51. Slide 51: Market Opportunity for HuMab 5B1

    MARKET OPPORTUNITY FOR HUMAB 5B1 — REPRESENTS POTENTIAL NEW TREATMENTS FOR MULTIPLE CANCERS Pancreatic Colon & Rectum Small Cell Lung Cancer Stomach Mi MabVax therepeutice 53,070 134,490 30,143 26,370 Deaths Yr /Y ul 41,780 7.7% 49,119 65% 20,100 14% 10,730 31% ' Global Data Disease Reports portunit

  52. Slide 52: Partnering Discussions

    PARTNERING DISCUSSIONS ¢ Active discussions with potential partners under CDA in progress. Multiple opportunities ¢ Antibody as targeting vehicle for development of a bi-specific, ADC or CAR-T product — Multiple domestic and Asian companies — Multiple indications ¢ Radioimmunotherapy product — Multi

  53. Slide 53: Key Milestones for HuMab5B1 Development Programs

    Key MILESTONES FOR HUMAB5B1 DEVELOPMENT PROGRAMS FOR 2016 AND 2017 Program MVT-5873 Therapeutic Monotherapy MVT-5873 Therapeutic Combination with Chemo MVT-2163 PET Imaging MVT-1075 Radio- Immunotherapy HuMab-5B1 ADC Miviesvex therepeutice 1H2016 VY Initiate dose escalation safety Phase I Trial Init

  54. Slide 54: Focused on Building Shareholder Value Near Term

    FOCUSED ON BUILDING SHAREHOLDER VALUE NEAR TERM 1. Encouraging data emerging from two clinical trials 2. Complete MVT-5873 phase Ia therapeutic clinical study and present data early in 2017. Define recommended phase II dose (RP2D) 3. Launch Phase 5873 phase Ib POC for maintenance treatment in PDAC 4

  55. Slide 55: Robust Intellectual Property

    ROBUST INTELLECTUAL PROPERTY 14 issued patents and 3 pending applications in the U.S. ¢ 13 issued US patents and 1 pending US application covering monovalent and polyvalent vaccines, methods of manufacture, methods of use ¢ 1 issued US patent and 2 pending US applications covering monoclonal antibod

  56. Slide 56: Strong Management Team and Board of Directors

    STRONG MANAGEMENT TEAM AND BOARD OF DIRECTORS anageme J. David Hansen Founder, President & CEO Board Member Philip Livingston, M.D. Founder & Chief Science Officer Gregory Hanson, CMA Chief Financial Officer Wolfgang Scholz, Ph.D. Founder & Vice President Antibody Discovery Paul Maffuid, Ph.D. Execu

  57. Slide 57: Company Contacts

    Mi MabVax therapeutics Immuno-Oncology Products Discovered From The Human Immune Response to Cancer Company Contacts J. David Hansen Gregory P. Hanson CMA MBA President and CEO Chief Financial Officer [email protected] [email protected] 858-500-8455 858-500-8457 Mi MabVax NASDAQ: MBVX | 57 t

MabVax Therapeutics Holdings — Technical Presentation (April 2017) on 6ix